Decourt 2020 / MCLENA-1
Study ID(s) and Acronym(s)
Current Status of Trial
Lenalidomide // Plavebo
Dosage and Duration
In this Phase II, proof-of mechanism study, 30 amnestic mild cognitive impairment (aMCI) subjects will be treated with lenalidomide at 10 mg/day for 12 months on a 1:1 ratio, followed by a 6 months washout period.
Absolute Number of Participants
Mild Cognitive Impairment (MCI) // aMCI